ArticleOncotarget2017
MerTK is a novel therapeutic target in gastric cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Apoptotic-Cell Accumulation and Mertk Expression Are Linked to Diminished Antiviral CD8Immune network · 2026Article
- A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells.Cancer research · 2026Article
- Idiopathic Pulmonary Fibrosis: Cellular Heterogeneity, Mechanisms, and Therapeutic Implications.MedComm · 2025Review
- Targeting MERTK tyrosine kinase: Virtual screening and molecular dynamics insights for anti-cancer drug development.PloS one · 2025Article
- Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024Review
- Establishment of a novel efferocytosis potential index predicts prognosis and immunotherapy response in cancers.Heliyon · 2024Article
- Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma.Cancer medicine · 2024Article
- N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth.Redox biology · 2022Article
- Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma.Frontiers in genetics · 2022Article
- Mertk: An emerging target in cancer biology and immuno-oncology.International review of cell and molecular biology · 2022Article
- TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?Expert opinion on therapeutic targets · 2021Review
- MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.Pharmacology & therapeutics · 2020Review
- Silencing of Long Non-Coding RNA Colon Cancer-Associated Transcript 2 Inhibits the Growth and Metastasis of Gastric Cancer Through Blocking mTOR Signaling.OncoTargets and therapy · 2020Article
- Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis.The European respiratory journal · 2019Article
- Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system.PloS one · 2019Article
- The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.Journal of hematology & oncology · 2018Article
- The TAM family as a therapeutic target in combination with radiation therapy.Emerging topics in life sciences · 2017Article
- Article
- Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.Oncotarget · 2017Article
- TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe role of MerTK has not been assessed in gastric cancer (GC). The aim of this study was to identify a subgroup of GC patients with MerTK tumor overexpression, and to evaluate MerTK as a potential therapeutic target in this disease.
methodsProtein and mRNA expression of MerTK were evaluated, and other various
resultsshRNA-mediated knockdown of MerTK resulted in inhibition of cell growth, as well as increased cellular apoptosis in MerTK positive GC cells. Out of 192 GC patients, 16 (8.3%) patients showed strong protein expression and they had a significantly shorter overall survival compared to those with no MerTK expression. In 54 cases of GC PDCs, 4 cases (7.4%) showed mRNA overexpression, which was comparable to the protein expression rate. When we administered UNC1062, a novel MerTK-selective small molecular tyrosine kinase inhibitor, proliferation of MerTK overexpressing GC cells and PDCs were considerably inhibited.
conclusionMerTK may be involved in GC carcinogenesis, and it could be a potential novel therapeutic target in GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.